Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Puma Biotechnology reports revenue growth and strategic advancements in oncology

Puma Biotechnology's Q4 2022 performance reflects revenue growth, cost reductions, and a focus on improving NERLYNX sales.
The company faces challenges in addressing financial losses, FDA trial requirements, and optimizing commercial strategies.
Opportunities in advancing clinical programs, FDA discussions, and market expansion present avenues for future growth and innovation.
Overall, Puma's strategic focus on revenue enhancement, cost control, and innovative treatments positions them for continued progress in the oncology market.

Puma Biotechnology reports solid Q1 earnings, eyes oncology expansion

Puma Biotechnology's Q1 2023 performance driven by strong NERLYNX sales and revenue growth.
Focus on in-licensing alisertib and optimizing expenses for sustained profitability.
Challenges include competition, patent issues, and trial enrollment hurdles.
Opportunities lie in expanding alisertib's indications and in-licensing assets for growth.

Puma Biotechnology reports revenue growth and advances in clinical trials

Puma Biotechnology's Q2 2023 performance showcased revenue growth driven by NERLYNX sales and promising results from alisertib trials. Despite challenges in NERLYNX prescriptions and FDA expectations, strategic initiatives aim to boost sales and advance clinical development. Opportunities in commercial strategies and clinical trials present avenues for future growth.

Puma Biotechnology reports solid Q3 earnings amidst sales challenges

Puma Biotechnology reported solid financial performance in Q3 2023 despite challenges in NERLYNX sales.
The company's focus on improving sales, pursuing clinical trials, and reducing expenses positions it for future growth.
Opportunities lie in enhancing NERLYNX sales, diversifying the product portfolio, and achieving clinical milestones.
Navigating challenges in sales and portfolio diversification while capitalizing on opportunities will be key for Puma's success.

Puma Biotechnology reports stable Q4 earnings amidst prescription challenges

Puma Biotechnology's Q4 2023 performance reflects solid revenue figures and a focus on profitability despite prescription declines.
The company's strengths lie in its innovative trials, commercial strategies, and optimistic revenue projections for the future.
Challenges include prescription decreases and inventory impacts, while opportunities exist in diversification, engagement enhancement, and market differentiation.

Puma Biotechnology reports revenue growth and strategic expansion plans

Puma Biotechnology's Q1 2024 performance reflects revenue growth and strategic initiatives to drive sales and enhance profitability.
While facing challenges in maintaining NERLYNX sales and managing expenses, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, financial stability, and market expansion, Puma is poised for continued growth and success in the biotechnology sector.
Investors should monitor Puma's progress in clinical trials, revenue diversification, and cost management for insights into its future performance.

Puma Biotechnology reports strong revenue, eyes product approvals for growth

Puma Biotechnology's Q2 2024 performance reflects solid revenue generation and strategic investment in innovation.
While facing challenges such as declining new prescriptions and a net loss, the company maintains a focus on cost management.
Opportunities lie in product approvals, revenue growth, and leveraging financial stability for future growth initiatives.
Overall, Puma's financial outlook remains positive, supported by a strong product pipeline and prudent financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released its financial results for the first quarter ended March 31, 2021, after market close on May 6, 2021.

Puma Biotechnology Reports First Quarter 2021 Financial Results

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Puma Biotech (PBYI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock?

Puma Biotech (PBYI) Down 6.3% Since Last Earnings Report: Can It Rebound?

Novartis

Celcuity

Celcuity Inc (NASDAQ: CELC) has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NYSE: NVS), and Puma Biotechnology Inc (NASDAQ: PUMA) to conduct a Phase 2 clinical trial. The open-label Phase 2 trial will evaluate the efficacy and safety of two targeted therapies, Novartis' Tabrecta, a c-Met inhibitor, and Puma's Nerlynx, a pan-HER inhibitor, in patients with previously treated metastatic HER2-negative breast cancer selected with Celcuity's CELsignia Multi-Pathway Activity Test.

Celcuity Teams Up With MD Anderson, Novartis, Puma Biotech To Study New Drug Regimen In Breast Cancer

ALLSCHWIL, Switzerland, March 05, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance today announced its financial results for the full-year of 2020 and provided a business update.

Polyphor Announces Financial Results for the Full-Year 2020

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO & President, will present an overview of Puma Biotechnology at the virtual Barclays Global Healthcare Conference on March 11, 2021.

Puma Biotechnology to Present at the Barclays Global Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at H.C. Wainwright's Global Health Care Conf, available online beginning March 9, 2021.

Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference

Puma Biotech (PBYI) reports wider-than-expected fourth-quarter loss while sales beat estimates.

Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall

Puma Biotechnology's (PBYI) CEO Alan Auerbach on Q4 2020 Results - Earnings Call Transcript

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Returns NERLYNX® Rights in Greater China to Puma Biotechnology as the Two Parties Terminate License Agreement and Settle Arbitration

CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration

LOS ANGELES & CASTRES, France--(BUSINESS WIRE)--Puma Biotechnology and Pierre Fabre added Greater China to their license agreement. Puma and CANbridge Pharma terminated their Greater China agreement

Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China

Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PST on February 25 following release of its 4Q-2020 financial results.

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented interim results from the Phase II SUMMIT Trial of Neratinib for EGFR exon 18-mutated, metastatic NSCLC at WCLC 2020.

Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present a company update at the B. Riley Oncology Investor Conference on Jan. 21.

Puma Biotechnology to Present at the B. Riley Oncology Investor Conference

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented interim results from its biliary tract cancers cohort of the Phase II SUMMIT “basket” trial at ASCO GI 2021,

Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at the J.P. Morgan Healthcare Conference on Jan. 14 at 10:50 a.m. EST.

Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present a Puma Biotechnology update at H.C. Wainwright's BioConnect VIRTUAL Conference beginning on Jan. 11, 2021 at 6:00 am EST.

Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference

Puma Biotechnology continues to report encouraging clinical data for its flagship product, NERLYNX. Unfortunately, the commercial numbers continue to remain in purgatory. I take a look at the company's recent earnings report to extract some key commercial metrics and trends that have developed over 2020.

Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented efficacy and safety outcomes from the Phase III NALA Trial in a Spotlight Poster at the 2020 Virtual SABCS.

Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented final overall survival analysis from its Phase III ExteNET Trial at the 2020 San Antonio Breast Cancer Symposium.

Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented updated results from its Phase II SUMMIT trial in a Spotlight Poster at the 2020 San Antonio Breast Cancer Symposium.

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020

Why Is Puma Biotech (PBYI) Up 36% Since Last Earnings Report?

LOS ANGELES--(BUSINESS WIRE)--European Patent Office Upholds Puma Biotechnology's Patent Position on EP 1848414 as Granted.

Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted

Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.

News for Puma Biotechnology Stock (PBYI)